Cargando…

Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor

A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4–C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pai...

Descripción completa

Detalles Bibliográficos
Autores principales: Kajiwara, Daisuke, Kamoda, Hiroto, Yonemoto, Tsukasa, Iwata, Shintaro, Ishii, Takeshi, Tsukanishi, Toshinori, Ohtori, Seiji, Yamazaki, Masashi, Okawa, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Spine Surgery 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917776/
https://www.ncbi.nlm.nih.gov/pubmed/27340537
http://dx.doi.org/10.4184/asj.2016.10.3.553
_version_ 1782438997658697728
author Kajiwara, Daisuke
Kamoda, Hiroto
Yonemoto, Tsukasa
Iwata, Shintaro
Ishii, Takeshi
Tsukanishi, Toshinori
Ohtori, Seiji
Yamazaki, Masashi
Okawa, Akihiko
author_facet Kajiwara, Daisuke
Kamoda, Hiroto
Yonemoto, Tsukasa
Iwata, Shintaro
Ishii, Takeshi
Tsukanishi, Toshinori
Ohtori, Seiji
Yamazaki, Masashi
Okawa, Akihiko
author_sort Kajiwara, Daisuke
collection PubMed
description A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4–C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence.
format Online
Article
Text
id pubmed-4917776
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Korean Society of Spine Surgery
record_format MEDLINE/PubMed
spelling pubmed-49177762016-06-23 Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor Kajiwara, Daisuke Kamoda, Hiroto Yonemoto, Tsukasa Iwata, Shintaro Ishii, Takeshi Tsukanishi, Toshinori Ohtori, Seiji Yamazaki, Masashi Okawa, Akihiko Asian Spine J Case Report A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4–C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence. Korean Society of Spine Surgery 2016-06 2016-06-16 /pmc/articles/PMC4917776/ /pubmed/27340537 http://dx.doi.org/10.4184/asj.2016.10.3.553 Text en Copyright © 2016 by Korean Society of Spine Surgery http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kajiwara, Daisuke
Kamoda, Hiroto
Yonemoto, Tsukasa
Iwata, Shintaro
Ishii, Takeshi
Tsukanishi, Toshinori
Ohtori, Seiji
Yamazaki, Masashi
Okawa, Akihiko
Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
title Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
title_full Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
title_fullStr Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
title_full_unstemmed Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
title_short Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
title_sort denosumab for treatment of a recurrent cervical giant-cell tumor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917776/
https://www.ncbi.nlm.nih.gov/pubmed/27340537
http://dx.doi.org/10.4184/asj.2016.10.3.553
work_keys_str_mv AT kajiwaradaisuke denosumabfortreatmentofarecurrentcervicalgiantcelltumor
AT kamodahiroto denosumabfortreatmentofarecurrentcervicalgiantcelltumor
AT yonemototsukasa denosumabfortreatmentofarecurrentcervicalgiantcelltumor
AT iwatashintaro denosumabfortreatmentofarecurrentcervicalgiantcelltumor
AT ishiitakeshi denosumabfortreatmentofarecurrentcervicalgiantcelltumor
AT tsukanishitoshinori denosumabfortreatmentofarecurrentcervicalgiantcelltumor
AT ohtoriseiji denosumabfortreatmentofarecurrentcervicalgiantcelltumor
AT yamazakimasashi denosumabfortreatmentofarecurrentcervicalgiantcelltumor
AT okawaakihiko denosumabfortreatmentofarecurrentcervicalgiantcelltumor